Skip to main content
NASDAQ:IBRX

ImmunityBio Competitors

$15.22
+0.76 (+5.26 %)
(As of 05/14/2021 12:19 PM ET)
Add
Compare
Today's Range
$14.28
$15.40
50-Day Range
$15.19
$30.89
52-Week Range
$4.15
$45.42
Volume19,063 shs
Average Volume1.43 million shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ImmunityBio (NASDAQ:IBRX) Vs. ABCM, SANA, RXRX, NUVB, IMCR, and SEER

Should you be buying IBRX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ImmunityBio, including Abcam (ABCM), Sana Biotechnology (SANA), Recursion Pharmaceuticals (RXRX), Nuvation Bio (NUVB), Immunocore (IMCR), and Seer (SEER).

ImmunityBio (NASDAQ:IBRX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Profitability

This table compares ImmunityBio and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
AbcamN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for ImmunityBio and Abcam, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Abcam04302.43

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 64.26%. Abcam has a consensus target price of $22.00, suggesting a potential upside of 10.11%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts clearly believe ImmunityBio is more favorable than Abcam.

Valuation & Earnings

This table compares ImmunityBio and Abcam's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

ImmunityBio beats Abcam on 2 of the 3 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Sana Biotechnology and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
ImmunityBioN/AN/AN/A

Valuation and Earnings

This table compares Sana Biotechnology and ImmunityBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Sana Biotechnology and ImmunityBio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
ImmunityBio00103.00

Sana Biotechnology currently has a consensus target price of $40.00, suggesting a potential upside of 100.80%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 64.26%. Given Sana Biotechnology's higher probable upside, research analysts clearly believe Sana Biotechnology is more favorable than ImmunityBio.

Summary

Sana Biotechnology beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Recursion Pharmaceuticals (NASDAQ:RXRX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Recursion Pharmaceuticals and ImmunityBio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Recursion Pharmaceuticals02302.60
ImmunityBio00103.00

Recursion Pharmaceuticals currently has a consensus price target of $33.20, indicating a potential upside of 52.08%. ImmunityBio has a consensus price target of $25.00, indicating a potential upside of 64.26%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Recursion Pharmaceuticals.

Valuation & Earnings

This table compares Recursion Pharmaceuticals and ImmunityBio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion PharmaceuticalsN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Recursion Pharmaceuticals and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Recursion PharmaceuticalsN/AN/AN/A
ImmunityBioN/AN/AN/A

Summary

ImmunityBio beats Recursion Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for ImmunityBio and Nuvation Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Nuvation Bio00603.00

ImmunityBio currently has a consensus price target of $25.00, indicating a potential upside of 64.26%. Nuvation Bio has a consensus price target of $17.40, indicating a potential upside of 56.33%. Given ImmunityBio's higher probable upside, research analysts plainly believe ImmunityBio is more favorable than Nuvation Bio.

Profitability

This table compares ImmunityBio and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Nuvation BioN/AN/AN/A

Earnings and Valuation

This table compares ImmunityBio and Nuvation Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Immunocore (NASDAQ:IMCR) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Profitability

This table compares Immunocore and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunocoreN/AN/AN/A
ImmunityBioN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immunocore01202.67
ImmunityBio00103.00

Immunocore currently has a consensus target price of $54.3333, indicating a potential upside of 32.52%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 64.26%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Immunocore.

Earnings & Valuation

This table compares Immunocore and ImmunityBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunocoreN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Summary

ImmunityBio beats Immunocore on 2 of the 3 factors compared between the two stocks.

Seer (NASDAQ:SEER) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Valuation & Earnings

This table compares Seer and ImmunityBio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Seer and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
ImmunityBioN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seer and ImmunityBio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
ImmunityBio00103.00

Seer currently has a consensus price target of $66.3333, suggesting a potential upside of 121.70%. ImmunityBio has a consensus price target of $25.00, suggesting a potential upside of 64.26%. Given Seer's higher possible upside, research analysts plainly believe Seer is more favorable than ImmunityBio.

Summary

Seer beats ImmunityBio on 2 of the 3 factors compared between the two stocks.


ImmunityBio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abcam logo
ABCM
Abcam
1.1$19.98+0.1%$4.53 billionN/A0.00
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$19.92+2.9%$3.63 billionN/A0.00Gap Up
RXRX
Recursion Pharmaceuticals
1.5$21.83+3.5%$3.41 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$11.13+1.4%$2.18 billionN/A0.00Analyst Downgrade
Immunocore logo
IMCR
Immunocore
1.3$41.00+0.6%$1.76 billionN/A0.00Gap Up
SEER
Seer
1.1$29.92+3.8%$1.75 billionN/A0.00Earnings Announcement
Analyst Report
BioAtla logo
BCAB
BioAtla
1.7$46.95+2.9%$1.53 billionN/A0.00Earnings Announcement
News Coverage
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.4$27.46+1.1%$1.21 billionN/A0.00News Coverage
EWTX
Edgewise Therapeutics
1.8$25.04+0.6%$1.20 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$26.01+3.1%$1.12 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$22.04+0.7%$964.98 millionN/A0.00News Coverage
Gap Up
CNTB
Connect Biopharma
1.7$16.20+4.3%$891.31 millionN/A0.00
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$27.90+11.4%$862.45 millionN/A0.00Earnings Announcement
News Coverage
Gap Up
STEM
Stem
0.0$18.14+9.7%$785.39 millionN/A0.00Gap Up
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$23.01+2.8%$784.86 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Pharming Group logo
PHAR
Pharming Group
0.0$11.91+9.2%$763.78 millionN/A0.00News Coverage
Gap Down
Vor Biopharma logo
VOR
Vor Biopharma
1.5$19.78+0.4%$731.50 millionN/A0.00Analyst Upgrade
Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.5$22.25+0.0%$708.44 millionN/A0.00Gap Up
FDMT
4D Molecular Therapeutics
1.3$26.85+1.6%$705.26 millionN/A0.00Earnings Announcement
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.32+0.1%$665.89 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.4$10.39+6.2%$655.33 millionN/A0.00News Coverage
Gap Up
FNCH
Finch Therapeutics Group
2.0$12.09+0.5%$567.15 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.15+1.1%$546.61 millionN/A0.00
VACC
Vaccitech
0.3$17.00+7.4%$536.51 millionN/A0.00News Coverage
Gap Up
ACHL
Achilles Therapeutics
1.6$13.65+7.6%$512.24 millionN/A0.00Earnings Announcement
Quiet Period Expiration
Analyst Revision
Gap Up
MIGI
Mawson Infrastructure Group
0.0$0.89+6.7%$471.73 millionN/A0.00Upcoming Earnings
BMEA
Biomea Fusion
1.7$16.80+5.3%$457.70 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
VECT
VectivBio
1.6$12.79+0.8%$431.65 millionN/A0.00Quiet Period Expiration
SGTX
Sigilon Therapeutics
1.4$13.25+6.0%$417.77 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.24+1.7%$412.78 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.5$10.30+1.0%$409.20 millionN/A0.00
RAIN
Rain Therapeutics
1.3$15.23+1.0%$391.61 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.15+7.7%$390.30 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.99+5.2%$380.90 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$9.42+8.5%$370.65 millionN/A0.00News Coverage
Gap Up
PRTG
Portage Biotech
0.0$28.65+2.1%$338.81 millionN/A0.00
HOWL
Werewolf Therapeutics
0.3$11.55+0.4%$319.45 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$9.65+5.7%$312.00 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
IMPL
Impel NeuroPharma
0.3$13.84+0.8%$270.84 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.40+9.1%$247.46 millionN/A-2.53
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.31+1.2%$233.40 millionN/A-2.29Earnings Announcement
VINC
Vincerx Pharma
1.0$16.34+1.0%$228.50 millionN/A0.00
RPHM
Reneo Pharmaceuticals
2.0$8.08+0.9%$193.93 millionN/A0.00Quiet Period Expiration
Gap Up
Annovis Bio logo
ANVS
Annovis Bio
1.7$24.23+3.9%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$6.99+8.6%$159.12 millionN/A0.00Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$8.58+2.1%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.85+4.5%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.37+3.9%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.